Company intelligence / Profile preview

Nanjing Delova Biotech Co., Ltd.

Nanjing, Jiangsu, Chinaen.delovabio.com ↗

Ownership: Private
Employees: ~50
Development stage: NDA

Overview

Delova Biotech’s lead product QP001 (Qamzova®, meloxicam injection) received FDA approval in April 2025 for moderate-to-severe pain management in adults. The company has nearly 10 non-opioid analgesics at various clinical development stages targeting unmet needs in both China and the US. Their platforms focus on improving drug delivery and efficacy of difficult-to-dissolve drugs with a strong emphasis on patent protection throughout the drug lifecycle.

Therapeutic areas: OtherRheumatologyNeurology
Modalities: Small moleculesSynthetic peptidesAntisense oligonucleotidesAptamersGene therapyRecombinant proteins
Industry: Biotech

Drug pipeline

1 asset

QP-6211

Unknown

Beyond the preview

Go deeper on Nanjing Delova Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Delova Biotech Co., Ltd..

Explore the full profile